03102nas a2200361   4500008004100000022001400041245012400055210006900179260001500248300001200263490000700275520200300282653002002285653002802305653001902333653003702352653001102389653001602400653001702416100003402433700002102467700002502488700002402513700001802537700001902555700002402574700002202598700002502620700002002645700001902665700002002684856003602704       2022                        eng d  a2047-998000aPlasma Levels of Advanced Glycation Endproducts and Risk of Cardiovascular Events: Findings From 2 Prospective Cohorts.0 aPlasma Levels of Advanced Glycation Endproducts and Risk of Card  c2022 08 02  ae0240120 v113 a<p>Background Advanced glycation endproducts (AGEs) have been linked to cardiovascular disease (CVD) in cohorts with and without diabetes. Data are lacking on prospective associations of various α-dicarbonyl-derived AGEs and incident CVD in the general population. We tested the hypothesis that major plasma AGEs are associated with new-onset CVD in 2 population-based cohorts of differing age and comorbidities. Methods and Results Analyses involved a random subcohort (n=466) from the Cardiovascular Health Study and a case-cohort sample (n=1631) from the Multi-Ethnic Study of Atherosclerosis. Five AGEs and 2 oxidative products were measured by liquid chromatography tandem mass spectrometry. Associations with CVD (myocardial infarction and stroke) were evaluated with Cox regression. Participants in the Cardiovascular Health Study were older than the Multi-Ethnic Study of Atherosclerosis, and had more comorbidities, along with higher levels of all AGEs. During median follow-up of 11 years, 439 participants in the Multi-Ethnic Study of Atherosclerosis and 200 in the Cardiovascular Health Study developed CVD. After multivariable adjustment, carboxymethyl-lysine, 3-deoxyglucosone hydroimidazolones and a summary variable of all measured AGEs (principal component 1) were significantly associated with incident CVD in the Cardiovascular Health Study (HRs [95% CI]: 1.20 [1.01, 1.42], 1.45 [1.23, 1.72], and 1.29 [1.06, 1.56], respectively), but not the Multi-Ethnic Study of Atherosclerosis. Oxidative products were not associated with CVD in either cohort. Conclusions We found α-dicarbonyl-derived AGEs to be associated with CVD in an older cohort, but not in a healthier middle-aged/older cohort. Our results suggest that AGEs may exert detrimental cardiovascular effects only under conditions of marked dicarbonyl and oxidative stress. Further investigation of α-dicarbonyl derivatives could lead to potential new strategies for CVD prevention in high-risk older populations.</p>10aAtherosclerosis10aCardiovascular Diseases10aCohort Studies10aGlycation End Products, Advanced10aHumans10aMiddle Aged10aRisk Factors1 aLamprea-Montealegre, Julio, A1 aArnold, Alice, M1 aMcClelland, Robyn, L1 aMukamal, Kenneth, J1 aDjoussé, Luc1 aBiggs, Mary, L1 aSiscovick, David, S1 aTracy, Russell, P1 aBeisswenger, Paul, J1 aPsaty, Bruce, M1 aIx, Joachim, H1 aKizer, Jorge, R  uhttps://chs-nhlbi.org/node/9170